Two medications are FDA-approved to treat tardive dyskinesia, and new long-term evidence has been reported. Learn more from Dr. Joseph McEvoy.

When should you rely on top-ranked treatment options for acute bipolar mania, and when should you skip down to lower-ranked options? Dr Suppes discusses.

Dr Suppes discusses guidelines for maintenance treatment of bipolar I disorder, with an algorithm for pharmacologic and psychosocial interventions.

What can you do to combat relapse in your patients with schizophrenia? Dr Lauriello discusses identifying and addressing nonadherence to antipsychotics.

Patient-reported outcomes are important for assessing the impact of schizophrenia and the success of treatment. Dr Correll discusses patient-centered care.

New treatments for schizophrenia may improve symptom domains other than positive symptoms and reduce adverse effects. Learn more in this CME activity.

In this CME activity, learn how to use patient-centered care to enhance medication adherence and aid functional recovery in schizophrenia.

Do you know how to talk with your patients about the risk for tardive dyskinesia? Follow along as Dr Nierenberg offers tips for clear communication.

Although clinicians are pressed for time, diligence in assessing for tardive dyskinesia in patients taking antipsychotics is crucial, especially now that treatment is available. In this brief CME activity, Dr Nierenberg describes the evaluation process. 

Subscribe to RSS - Antipsychotics